Hybio Pharmaceutical Co., Ltd., a national high-tech enterprise, specialized in R&D, production and marketing of peptide drugs, with a focus on peptide drugs and Oligonucleotide Drug. Listed on the Shenzhen Stock Exchange in 2011 (stock code: 300199), it is among China's earliest listed peptide drug companies.
Boasting national-level platforms like the National and Local Joint Engineering Laboratory for Peptide Drugs, it has undertaken multiple national projects and won honors including the Second Prize of National Technological Invention Award, China Patent Excellence Award, and entitled as National Intellectual Property Demonstration Enterprise.
GMP certified by China NMPA, US FDA, EU EMA, Brazil ANVISA, Australia TGA, Indonesian BPOM, South Korea MFDS, etc., it has built a vertical integrated industrial chain covering API、finished dosage and marketing, securing supply chain from raw materials to drugs. Adhering to the vision of continuous innovation to lead the peptide industry, Hybio takes protecting life and health as its eternal mission.